Multi Component Antibody Based Detection Technology
Cell Signaling Technology, Inc.
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/US2012/048587, filed Jul 27, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,588,110 | Multi Component Antibody Based Detection Technology In force · High confidence | Cell Signaling Technology, Inc. | In force | High confidence | ||
| US 10,577,640 | Multi Component Detection In force · High confidence | Cell Signaling Technology, Inc. | In force | High confidence | ||
| Application 16/800,394 | Multi Component Detection Abandoned Abandoned Mar 29, 2023 | Cell Signaling Technology, Inc. | Abandoned | Abandoned Mar 29, 2023 |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Cell Signaling Technology, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.